15 July 2021>: Articles
Isolated Adrenocorticotropic Hormone Deficiency Associated with Severe Hyperkalemia During Pembrolizumab Therapy in a Patient with Ureteral Cancer and an Ileal Conduit: A Case Report and Literature Review
Unusual clinical course
Yudai Hinata B , Nobumasa Ohara A* , Yuhki Sakurai C , Ryo Koda B , Yuichiro Yoneoka C , Toshinori Takada C , Noboru Hara B , Tsutomu Nishiyama BDOI: 10.12659/AJCR.931639
Am J Case Rep 2021; 22:e931639
B: Corticotropin-releasing hormone (CRH)/growth hormone-releasing factor (GRF)/thyrotropin-releasing hormone (TRH)/luteinizing hormone-releasing hormone (LHRH) stimulation test (November 2019).
Reference range* | Basal | Peak (time at peak) | |
---|---|---|---|
Adrenocorticotropic hormone (pg/mL) | 7.2–63.3 | 11.6 | 16.7 (60 min) |
Cortisol (μg/dL) | 7.1–19.6 | 2.2 | 2.9 (90 min) |
Growth hormone (ng/mL) | 0–2.47 | 1.5 | 13.6 (15 min) |
Thyroid-stimulating hormone (μIU/mL) | 0.50–5.00 | 2.86 | 19.84 (30 min) |
Prolactin (ng/mL) | 6.1–30.5 | 20.8 | 53.9 (30 min) |
Luteinizing hormone (mIU/mL) | 0.8–5.7 | 23.2 | 52.6 (90 min) |
Follicle-stimulating hormone (mIU/mL) | 2.0–8.3 | 49.8 | 62.1 (120 min) |
Blood samples were collected in the morning before (basal) and at 15, 30, 60, 90, and 120 min after i.v. administration of the following: 100 μg of CRH, 100 μg of GRF, 500 μg of TRH, and 100 μg of LHRH. |